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Tetherin (BST-2 or CD317) is an interferon-inducible
transmembrane protein that inhibits virus release
from infected cells. Whereas HIV-1 Vpu and HIV-2
Env counteract human tetherin, most SIVs use Nef to
antagonize the tetherin proteins of their nonhuman
primate hosts. Here, we show that compensatory
changes in the cytoplasmic domain of SIV gp41,
acquired by a nef-deleted virus that regained a patho-
genic phenotype in infected rhesus macaques,
restore resistance to tetherin.Thesechanges facilitate
virus release in thepresenceof rhesus tetherin,butnot
human tetherin, and enhance virus replication in inter-
feron-treated primary lymphocytes. The substitutions
in gp41 result in a selective physical association with
rhesus tetherin, and the internalization andsequestra-
tion of rhesus tetherin by a mechanism that depends
on a conserved endocytosis motif in gp41. These
results are consistent with HIV-2 Env antagonism of
human tetherin and suggest that the ability to oppose
tetherin is important for lentiviral pathogenesis.
INTRODUCTION
Mammalian cells have evolved a number of restriction factors to
interfere with different stages of virus replication (Wolf and Goff,
2008). One such factor, tetherin (BST-2, CD317, or HM1.24),
impairs the detachment of enveloped viruses from infected cells
(Kaletsky et al., 2009; Neil et al., 2007, 2008; Van Damme et al.,
2008). Tetherin is a type II integral membrane protein with
a topology that allows both ends of the protein to be anchored
in lipid membranes (Kupzig et al., 2003). It has an N-terminal
cytoplasmic domain followed by a transmembrane domain, an
extracellular coiled-coil domain, and a C-terminal glycosyl-
phosphatidylinositol (GPI) anchor (Kupzig et al., 2003; Rollason
et al., 2007). Under conditions of interferon-induction, tetherin
is upregulated and becomes incorporated into virus particles
as they attempt to bud from infected cells (Fitzpatrick et al.,
2010; Hammonds et al., 2010; Perez-Caballero et al., 2009).
Recent evidence suggests that tetherin forms a parallel homo-
dimer that physically bridges nascent virus particles to infected46 Cell Host & Microbe 9, 46–57, January 20, 2011 ª2011 Elsevier Incells (Perez-Caballero et al., 2009). Captured virions are then
internalized and routed to endosomal compartments for degra-
dation by a mechanism that involves interactions of the cyto-
plasmic domain of tetherin with the endocytosis machinery of
the cell and with BCA2 (breast cancer-associated gene 2) (Gott-
linger, 2008; Miyakawa et al., 2009; Perez-Caballero et al., 2009).
Tetherin has a broad spectrum of antiviral activity against
diverse families of enveloped viruses, including retroviruses,
filoviruses, herpesviruses, and arenaviruses (Jouvenet et al.,
2009; Mansouri et al., 2009; Sakuma et al., 2009). Many of these
viruses have in turn evolved specific countermeasures to tetherin
(Jia et al., 2009; Kaletsky et al., 2009; Le Tortorec and Neil, 2009;
Neil et al., 2008; Van Damme et al., 2008; Zhang et al., 2009).
Among the primate lentiviruses, three different viral gene
products are known to antagonize tetherin. Whereas HIV-1
Vpu and HIV-2 Env antagonize human tetherin (Le Tortorec
and Neil, 2009; Neil et al., 2008; Van Damme et al., 2008), the
majority of simian immunodeficiency viruses (SIVs) use Nef to
counteract the tetherin proteins of their simian hosts (Jia et al.,
2009; Sauter et al., 2009; Zhang et al., 2009).
A role for Nef in counteracting restriction by tetherin may help
to explain the attenuated phenotype of nef-deleted SIV in rhesus
macaques (Kestler et al., 1991). In SIV Dnef-infected macaques,
peak viral loads are typically two to three logs lower than peak
viral loads in wild-type SIV-infected animals, and chronic phase
viral loads are often contained below the limit of detection
(Kestler et al., 1991). Nevertheless, a certain percentage of
animals infected with nef-deleted SIV develop moderate viral
loads and progress to AIDS after prolonged periods of persistent
infection (Alexander et al., 2003; Baba et al., 1995, 1999; Wyand
et al., 1997). This increase in replicative capacity reflects the
accumulation of genetic changes that restore a pathogenic
phenotype, since nef-deleted viruses isolated from animals
that progress to disease also cause disease in newly infected
animals (Alexander et al., 2003).
Here, we show that a pathogenic clone of SIV Dnef, containing
nucleotide changes acquired after serial passage of nef-deleted
SIV in rhesus macaques (Alexander et al., 2003), is resistant to
restriction by rhesus tetherin. This resistance mapped to specific
amino acid substitutions in the cytoplasmic domain of gp41 that
confer resistance to rhesus tetherin, but not to human tetherin.
These compensatory changes result in the selective coimmuno-
preciptation of Env with rhesus tetherin, facilitate virus replica-
tion in interferon-treated lymphocytes, and promote the
internalization and sequestration of tetherin in infected primaryc.
Figure 1. Compensatory Genetic Changes
in SIV DnefP Confer Resistance to Rhesus
Tetherin
Wild-type SIV, SIV Dnef, and SIV DnefP were
tested for virus release in the presence of human
tetherin (hBST-2), and three different alleles of rhe-
sus tetherin (rBST-2.1, rBST-2.2 and rBST-2.8;
see Figure S1). Virus release is shown at
increasing amounts of plasmid DNA for hBST-2
(A), rBST-2.1 (B), rBST-2.2 (C), and rBST-2.8 (D).
The amount of virus released into the cell culture
supernatant was determined by SIV p27 antigen-
capture ELISA 48 hr after transfection from dupli-
cate transfections, and the mean and standard
deviation (± error bars) were calculated as
a percentage of maximal virus release in the
absence of tetherin. The accumulation of virion-
associated p27 in the cell culture supernatant
was compared to Env and p55 Gag in cell lysates
by western blot analysis (E). See also Figure S1.
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Changes in SIV gp41 Afford Resistance to Tetherinlymphocytes. These results are entirely consistent with a role for
the HIV-2 envelope glycoprotein in counteracting human tetherin
(Abada et al., 2005; Bour et al., 1996; Le Tortorec and Neil, 2009)
and suggest that the ability to overcome restriction by tetherin is
particularly important for lentiviral pathogenesis.
RESULTS
Compensatory Genetic Changes Acquired
by a Pathogenic, nef-Deleted Strain of SIV Confer
Resistance to Rhesus Tetherin
Analysis of the nucleotide sequence changes acquired by
pathogenic isolates of nef-deleted SIV after serial passage inCell Host & Microbe 9, 46–5rhesus macaques revealed the accumu-
lation of changes in three regions of the
viral genome (Alexander et al., 2003).
These included a cluster of nonsynony-
mous changes in env coding for amino
acid substitutions in the gp41 cyto-
plasmic domain, an expanded deletion
of nef sequences overlapping with U3,
and a duplication of the NF-kB binding
site (Alexander et al., 2003). By
engineering these changes back into
SIVmac239 Dnef, Alexander et al. demon-
strated that the changes in the gp41 tail
(termed ITM for improved transmem-
brane), and an additional 278 bp deletion
in U3 (DU3), were sufficient for
pathogenesis (Alexander et al., 2003).
Since the envelope glycoproteins of
certain HIV-2 isolates can counteract
tetherin (Abada et al., 2005; Hauser
et al., 2010; Jia et al., 2009; Le Tortorec
and Neil, 2009), we hypothesized that
these compensatory changes, particu-
larly the ITM changes in gp41, might
provide resistance to tetherin.To test this hypothesis, we compared virus release for SIV
ITMDnefDU3, which we refer to hereafter as SIV DnefP, to virus
release for SIV Dnef and wild-type SIV at increasing expression
levels of human and rhesus tetherin. Since tetherin is
polymorphic in the rhesus macaque (McNatt et al., 2009), we
tested three different alleles: rBST-2.1, rBST-2.2, and rBST-2.8
(Figure S1 available online). rBST-2.1 and rBST-2.2 represent
common alleles, whereas rBST-2.8 was cloned from cryopre-
served PBMCs of the animal from which the compensatory
changes in SIV DnefP were first isolated. Wild-type SIV, SIV
Dnef, and SIV DnefP all exhibited similar susceptibility to
restriction by human tetherin (Figure 1A). However, these viruses
differed in their susceptibility to rhesus tetherin. Whereas SIV7, January 20, 2011 ª2011 Elsevier Inc. 47
Figure 2. The Compensatory Changes in SIV DnefP Enhance Virus
Replication in Interferon-Treated Rhesus Macaque Lymphocytes
Activated primary rhesus macaque lymphocytes were infected with wild-type
SIV, SIV Dnef, and SIV DnefP. On day 2 after infection, the cultures were
divided and maintained in medium with or without IFNa. The upregulation of
tetherin on CD4+ lymphocytes was verified by flow cytometry 24 hr after treat-
ment with IFNa (A). Virus replication wasmonitored by the accumulation of p27
in the supernatant for cultures maintained without (B, D, and F) or with (C, E,
and G) 100 U/ml IFNa.
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DnefP were resistant to all three alleles. In the presence of
rBST-2.1 and rBST-2.8, the release of SIV DnefP was similar to
wild-type SIV (Figures 1B and 1D). However, in the presence of
rBST-2.2, the release of SIV DnefP was higher than SIV Dnef,
but did not reach the same levels as wild-type virus (Figure 1C).
This difference may reflect the incomplete adaptation of SIV
DnefP to rBST-2.2, since the predicted amino acid sequence
of this allele differs from both rBST-2.1 and rBST-2.8 by three
residues (D14G, V29I and P159S) (Figure S1). Nevertheless, for
each of the rBST-2 alleles that were tested, virus release for
SIV DnefP was consistently higher than for SIV Dnef, indicating
that the compensatory changes acquired by SIV DnefP afford
broad resistance to different alleles of rhesus tetherin.
The resistance of SIV DnefP to restriction by rhesus tetherin
was corroborated by western blot analysis. Consistent with
previous observations (Jia et al., 2009), cell-associated Env
and p55 Gag levels diminished under conditions of tetherin
overexpression for each of the three viruses. However, at
increasing expression levels of rhesus tetherin (rBST-2.1), the
accumulation of p27 in the cell culture supernatant was consis-
tently greater for SIV DnefP than for SIV Dnef (Figure 1E). More-
over, similar to wild-type SIV, virion-associated p27 remained
detectable for SIV DnefP, even at the highest expression levels
of rhesus tetherin (Figure 1E). Hence, these results further indi-
cate that the compensatory changes in SIV DnefP afford resis-
tance to the inhibitory effects of rhesus tetherin on virion release.
The Compensatory Changes in SIV DnefP Facilitate
Virus Replication under Conditions of Interferon-
Induced Upregulation of Tetherin
To determine whether the compensatory changes in SIV DnefP
enhance virus replication under more physiological conditions
of tetherin expression, virus replication was assessed in inter-
feron-treated rhesus macaque lymphocytes. Activated PBMCs
from three different animals were infected with wild-type SIV,
SIV Dnef, and SIV DnefP. On day 2 after infection, the cultures
were divided and maintained in medium with or without IFNa.
The upregulation of tetherin on CD4+ lymphocytes was verified
by flow cytometry (Figure 2A), and virus replication was moni-
tored by the accumulation of SIV p27 in the cell culture superna-
tant (Figures 2B–2G). In the absence of IFNa, each of the viruses
replicated with similar kinetics (Figures 2B, 2D, and 2F). Treat-
ment with IFNa suppressed the replication of all three viruses.
However, whereas SIV Dnef was severely inhibited, SIV DnefP
and wild-type SIV were more resistant and replicated to similar
levels (Figures 2C, 2E, and 2G). Therefore, the changes acquired
by SIV DnefP facilitate virus replication under conditions of inter-
feron-induced upregulation of tetherin in primary rhesus
macaque lymphocytes.
AminoAcid Substitutions in theCytoplasmic Tail of gp41
Afford Resistance to Rhesus Tetherin
To identify the sequence changes in SIV DnefP that confer resis-
tance to rhesus tetherin, the ITM and DU3 mutations were intro-
duced separately into SIV Dnef (Figure 3A), and these recombi-
nant proviruses were tested for their susceptibility to restriction
by rhesus tetherin (Figure 3B). While the U3 deletion resulted
in a marginal increase in virus release relative to SIV Dnef48 Cell Host & Microbe 9, 46–57, January 20, 2011 ª2011 Elsevier In(<2-fold), the ITM changes restored virus release to the same
level as SIV DnefP (Figure 3B). The envelope glycoprotein of
SIV DnefP, EnvITM, was therefore tested for the ability to rescue
particle release for an env- and nef-deleted strain of SIV in the
presence of rhesus tetherin. EnvITM, but not wild-type Env,
restored the release of SIV DenvDnef to a level approaching
the extent of virus release afforded by Nef, as measured byc.
Figure 3. Amino Acid Substitutions in the Cytoplasmic
Domain of gp41 Account for the Resistance of SIV
DnefP to Rhesus Tetherin
(A) The ITM andDU3 changes were engineered separately into
SIV Dnef.
(B) These recombinant proviruseswere tested for virus release
in the presence of increasing amounts of an expression
construct for rhesus tetherin (rBST-2.1).
(C and D) Wild-type Env, EnvITM, and Nef were tested for the
ability to rescue particle release for SIV DenvDnef in the pres-
ence of rhesus tetherin. Virus release was measured by SIV
p27 antigen-capture ELISA (C) and corroborated by compar-
ison of virion-associated p27 in cell culture supernatant to
p55 Gag in cell lysates by western blot analysis (D).
Error bars (B) and (C) represent the standard deviation (±) of
mean percent maximal virus release. See also Figure S2.
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ysis (Figure 3D). Thus, the envelope glycoprotein expressed by
SIV DnefP antagonizes restriction by rhesus tetherin.
Additional sequence changes were identified in the remainder
of the nef open-reading frame, not reported in the initial descrip-
tion of SIV DnefP (Alexander et al., 2003), which encode a unique
94 amino acid polypeptide we refer to as pseudo-Nef (cNef)
(Figure S2A). To determine whether cNef contributes to the
antagonism of rhesus tetherin, we cloned this sequence into
an expression vector and tested for the ability to rescue the
release of SIV Dnef in the presence of rhesus tetherin. Whereas
wild-type Nef rescued virus release as previously described
(Jia et al., 2009), no increase in virus release was observed for
cNef (Figures S2B and S2C).
To determine whether cNef or EnvITM acquired other Nef
functions that might contribute to the increased replicative
capacity of SIV DnefP, we tested cNef and EnvITM for MHC
class I and CD4 downregulation, two functional activities that
involve distinct Nef sequences and cellular mechanisms (Roeth
and Collins, 2006). Neither cNef nor EnvITM resulted in a detect-
able decrease in MHC class I expression (Figure S2D). Consis-
tent with binding to CD4 as a receptor, wild-type Env and EnvITM
both downregulated CD4 (Figure S2E). cNef also resulted in
a slight, but reproducible, decrease in the surface expression
of CD4 (Figure S2E). However, since the extent of CD4 downre-
gulation by cNef was marginal compared to wild-type Nef
(1.6-fold versus 6.1-fold) and was only detectable under condi-
tions of protein overexpression, it is unclear to what extent this
activity contributes to the replication of SIV DnefP.Cell Host & MicrobTo identify the specific amino acid changes in
Env that confer resistance to rhesus tetherin,
subsets of the ITM changes were introduced into
SIV Dnef, and these mutants were tested for resis-
tance to increasing expression levels of rhesus
tetherin. Five amino acid substitutions at the C
terminus of gp41 (IRATT) were sufficient for resis-
tance to rhesus tetherin (Figures 4A, 4B, and 4C).
In contrast, neither the first six substitutions at the
N terminus (PIGPAH) nor three substitutions in the
central region (IFE) of the gp41 tail had a significant
effect on virus release (Figures 4A, 4B, and 4C).
Subsets of the IRATT changes were also testedand found to have partial effects on resistance to rhesus tetherin
(Figure S3). Thus, the ability of SIV DnefP to overcome restriction
by rhesus tetherin depends on a combination of five residues at
the C terminus of gp41.
A conserved tyrosine-based endocytosis motif (GYXXF) in the
membrane-proximal region of the gp41 tail was previously
shown to be required for HIV-2 Env antagonism of tetherin
(Abada et al., 2005; Le Tortorec and Neil, 2009; Noble et al.,
2006). We therefore asked whether this motif might also be
important for EnvITM antagonism of rhesus tetherin. A tyrosine
to alanine substitution was introduced at position 721 (Y721A)
of EnvITM in the context of SIV ITMDnef, and this mutant was
tested for virus release in the presence of rhesus tetherin. This
single amino acid substitution completely abrogated resistance
to rhesus tetherin (Figures 4D and 4E). Hence, SIV EnvITM and
HIV-2 Env appear to use similar mechanisms to antagonize teth-
erin that depend on the membrane-proximal endocytosis motif
in gp41.
Amino Acid Differences in the N Terminus of Tetherin
Account for the Resistance of SIV DnefP to Rhesus
Tetherin, but Not to Human Tetherin
Recombinants between human and rhesus tetherin were con-
structed to identify the residues responsible for the differential
ability of these two proteins to restrict SIV DnefP. Sequences
coding for the cytoplasmic domain (N) were exchanged to
generate rN/hBST-2 and hN/rBST-2, and sequences coding for
the transmembrane domain (TM) were exchanged to generate
rTM/hBST-2 and hTM/rBST-2. These recombinants were thene 9, 46–57, January 20, 2011 ª2011 Elsevier Inc. 49
Figure 4. Identification of Residues in the
gp41 Cytoplasmic Domain Required for the
Resistance of SIV DnefP to Rhesus Tetherin
(A) The gp41 cytoplasmic domains of SIV DnefP
(EnvITM) and wild-type SIVmac239 (Env) differ by
14 amino acids.
(B and C) Subsets of the ITM changes were intro-
duced into SIV Dnef and tested for virus release in
the presence of rhesus tetherin (rBST-2.1) by p27
antigen-capture ELISA (B) and by western blot
analysis (C). These proviral constructs included
six substitutions in the N terminus (PIGPAH), three
substitutions in the central region (IFE), and five
substitutions in the C terminus (IRATT) of the
gp41 tail (see also Figure S3).
(D and E) A tyrosine to alanine substitution was
introduced at position 721 (Y721A) in the context
of SIV ITMDnef, and differences in the release of
SIV Dnef, SIV ITMDnef and SIV Y721A ITMDnef
were compared by p27 antigen-capture ELISA
(D) and by western blot analysis (E) in the presence
of rhesus tetherin.
Error bars in (B) and (D) represent the standard
deviation (±) of mean percent maximal virus
release. See also Figure S3.
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DnefP was restricted by hN/rBST-2 and rTM/hBST-2, but not
by rN/hBST-2 or hTM/rBST-2 (Figures 5A and 5B). Thus, similar
to wild-type SIV, the resistance of SIV DnefP is dependent on
sequences in the cytoplasmic domain of rhesus tetherin.
To identify the cytoplasmic domain residues that account for
the selective resistance of SIV DnefP to rhesus tetherin, we intro-
duced amino acid substitutions at positions that differ from
human tetherin (Figure 5C). Neither disruption of the
D14DIWK18 sequence in rhesus tetherin (rBST-2 AAAAA) nor
the introduction of these residues into human tetherin (hBST-2
DDIWK) changed the pattern of restriction (Figure 5D). However,
deletion of the first ten amino acids of rhesus tetherin (rBST-2
D10) resulted in the inhibition of virus release, indicating that
these residues are essential for the ability of SIV DnefP to over-50 Cell Host & Microbe 9, 46–57, January 20, 2011 ª2011 Elsevier Inc.come restriction (Figure 5D). When resi-
dues 3–5 and 9–11 of rhesus tetherin
were replaced with the corresponding
residues of human tetherin (rBST-2
STS+CRV), SIV DnefP became suscep-
tible to restriction. Conversely, the recip-
rocal amino acid replacements (hBST-2
PIL+RKM) alleviated restriction by human
tetherin (Figure 5D). However, only partial
effects were observed when residues 3–5
and 9–11 were exchanged separately
(Figure 5D). Thus, the resistance of SIV
DnefP is dependent on a combination of
six residues at the N terminus of rhesus
tetherin, P3IL+R9KM, that differ from the
corresponding residues of human teth-
erin. Perhaps not coincidentally, these
sequences partially correspond to resi-
dues of human tetherin (S3TS) recentlyidentified as sites of Vpu-mediated ubiquitination (Tokarev
et al., 2010).
EnvITM Selectively Coimmunoprecipites with Rhesus
Tetherin
The ability of EnvITM to physically associate with rhesus tetherin
was examinedby coimmunoprecipitation. Tetherinwas immuno-
precipitated from lysates of 293T cells cotransfected with
constructs expressing wild-type or mutant forms of human and
rhesus tetherin, and either Env, EnvITM, or EnvITM Y721A. Immu-
noprecipitated proteins were separated by SDS-PAGE, and
western blots were probed with monoclonal antibodies to SIV
gp120 and to tetherin. EnvITM coimmunoprecipitated with
rhesus tetherin, but not with human tetherin (Figure 6A). A weak
association between wild-type Env and rhesus tetherin was
Figure 5. Identification of Residues in the Cytoplasmic Domain of Rhesus Tetherin that Confer Susceptibility to SIV DnefP
Sequences coding for the cytoplasmic (N) and transmembrane (TM) domains of human and rhesus tetherin (rBST-2 and hBST-2) were exchanged to generate
expression constructs for the following recombinants: rN/hBST-2, hN/rBST-2, rTM/hBST-2, and hTM/rBST-2. Virus release from 293T cells cotransfected with
SIV DnefP proviral DNA and increasing amounts of each of the tetherin recombinants (2, 20, 100, and 200 ng) was determined by p27 antigen-capture ELISA (A)
and verified by western blot analysis (B). The indicated amino acid substitutions and deletions were introduced into the cytoplasmic domains of rhesus and
human tetherin (C). These mutants were tested for the ability to inhibit virus release for SIV DnefP (D). The expression of Env and each of the tetherin mutants
was verified by western blot analysis of cell lysates. Error bars in (A) and (D) represent the standard deviation (±) of mean percent maximal virus release.
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fold more EnvITM than wild-type Env immunoprecipitated with
rhesus tetherin, as reflected by comparisons of the ratios of
Env to BST-2 in immunoprecipitates (Env IP/BST-2 IP) or immu-
noprecipitated Env to total Env in whole-cell lysates (Env IP/Env
input) (Figure 6A). Thus, the ITM changes appear to stabilize
a basal association between wild-type Env and rhesus tetherin.
To determine whether residues 3–5 and 9–11 contribute to the
specificity of this interaction, we tested EnvITM binding to teth-
erin mutants in which these sequences were exchanged
between human and rhesus tetherin. Introduction of the P3IL
and R9KM residues from rhesus tetherin into human tetherin
(hPIL+RKM) resulted in a detectable interaction with EnvITM
(Figure 6A). Conversely, replacement of these sequences in
rhesus tetherin with the corresponding residues of human teth-
erin (rSTS+CRV) diminished, but did not eliminate, this interac-
tion (Figure 6A). These results are therefore consistent with the
effects of amino acid changes at positions 3–5 and 9–11 on
the susceptibility of SIVDnefP to restriction and reveal a selective
physical interaction between EnvITM and rhesus tetherin.CellSince the P3IL and R9KM residues flank a conserved dual tyro-
sine-based endocytosis motif at positions 6–8 (Rollason et al.,
2007), this motif was disrupted with alanine substitutions
(rYDY/AAA) to determine whether EnvITM binding was also
dependent on these sequences. Although these mutations
significantly impaired virus release for SIV DnefP (Figure 6B),
they did not impair binding to EnvITM (Figure 6A). Likewise, the
Y721Amutation in EnvITM (EnvITM Y721A), which abrogated virus
release (Figures 4D and 4E), did not have a significant effect on
binding to rhesus tetherin (Figure 6A). These results indicate
that a physical interaction between EnvITM and rhesus tetherin
is not sufficient for antagonism and that these motifs may be
required for interactions with cellular factors, possibly AP-2
proteins involved in clatharin-mediated endocytosis.
An alanine to aspartate substitution in the ectodomain of
human tetherin (A100D) was recently shown to disrupt antago-
nism by SIVagmTan and HIV-2 Env (Gupta et al., 2009; Lopez
et al., 2010). We therefore introduced the corresponding muta-
tion into rhesus tetherin (A103D) to determinewhether this residue
is also important for the interaction with EnvITM. ThisHost & Microbe 9, 46–57, January 20, 2011 ª2011 Elsevier Inc. 51
Figure 6. EnvITM Selectively Coimmunoprecipitates with Rhesus Tetherin
(A) Tetherin was immunoprecipitated from 293T cells cotransfected with constructs expressing wild-type or mutant forms of rhesus and human tetherin, and
either Env, EnvITM, or EnvITM Y721A. Western blots were probed with monoclonal antibodies to Env and tetherin. The ratios of the relative band intensities
for Env, EnvITM, and EnvITM Y721A to BST-2 in immunoprecipitates (Env IP/BST-2 IP) and to total Env in whole-cell lysates (Env IP/Env input) are indicated.
The results shown are representative of three independent experiments.
(B) Mutations in the dual tyrosine-based endocytosismotif (YDY/AAA) and position 103 in the ectodomain (A103D) of rhesus tetherin were tested for their effects on
the restriction of SIV DnefP, and the expression of Env and BST-2 was verified by western blot analysis of cell lysates.
(C) CD4 fusions with the cytoplasmic domains of Env and EnvITM (CD4-Env and CD4-ITM), and with the transmembrane and cytoplasmic domains of these
proteins (CD4-TM-Env and CD4-TM-ITM), were tested for the ability to rescue particle release for SIV DenvDnef in the presence of rhesus tetherin (rBST-2.1).
Virus release wasmeasured by p27 antigen-capture ELISA and verified by comparing virion-associated p27 in supernatant to p55 in cell lysates. Error bars repre-
sent the standard deviation of mean percent maximal virus release.
(D) CD4-Env fusion proteins were tested for a physical interaction with rhesus tetherin. Tetherin was immunoprecipitated from 293T cells cotransfected with
constructs expressing rBST-2.1 and either CD4, CD4-Env, CD4-ITM CD4-TM-Env, or CD4-TM-ITM. Western blots were probed with antibodies to CD4 and
BST-2. The ratios of the relative band intensities for each of the CD4-Env proteins to BST-2 in immunoprecipitates (CD4-Env IP/BST-2 IP) and to total CD4-Env
in whole-cell lysates (CD4-Env IP/CD4-Env input) are indicated.
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Changes in SIV gp41 Afford Resistance to Tetherin
52 Cell Host & Microbe 9, 46–57, January 20, 2011 ª2011 Elsevier Inc.
Cell Host & Microbe
Changes in SIV gp41 Afford Resistance to Tetherinsubstitution did not impair binding to EnvITM (Figure 6A) or the
release of SIV DnefP (Figure 6B). Therefore, unlike SIVagmTan
or HIV-2 Env antagonism of human tetherin, this particular
residue is not critical for the ability of EnvITM to oppose rhesus
tetherin.
To determine whether the cytoplasmic domain of EnvITM is
sufficient to counteract rhesus tetherin, heterologous CD4-Env
fusion proteins were tested for the ability to rescue particle
release for an env- and nef-deleted strain of SIV. Constructs
were engineered to express the ectodomain and transmem-
brane domain of CD4 fused to the cytoplasmic tail of Env or
EnvITM (CD4-Env and CD4-ITM), or the ectodomain of CD4
fused to the transmembrane and cytoplasmic domains of Env
or EnvITM (CD4-TM-Env and CD4-TM-ITM). Western blot anal-
ysis of transfected cell lysates revealed two bands for each of
the CD4 fusion proteins, suggesting proteolytic degradation.
Nevertheless, CD4-ITM, and to a lesser extent CD4-TM-ITM,
but not CD4-Env or CD4-TM-Env, restored particle release to
similar levels as the complete EnvITM protein (Figure 6C).
The CD4-Env chimeras were then tested for a physical associ-
ation with rhesus tetherin by coimmunoprecipitation. Consistent
with the results obtained with the intact Env proteins, these inter-
actions were stronger for the CD4 fusions containing the cyto-
plasmic tail of EnvITM (CD4-ITMandCD4-TM-ITM) than for those
containing the cytoplasmic tail of Env (CD4-Env and CD4-TM-
Env) (Figure 6D). Approximately 3.3- to 3.7-fold more CD4-ITM
than CD4-Env, and 2.2- to 4.6-fold more CD4-TM-ITM than
CD4-TM-Env, immunoprecipitated with rhesus tetherin (Fig-
ure 6D). Themembrane-spanning domain of Env does not appear
to contribute to this interaction, since inclusion of these
sequences diminished the binding of CD4-TM-Env relative to
CD4-Env and CD4-TM-ITM relative to CD4-ITM. Thus, the cyto-
plasmicdomainofEnvITM issufficient tostabilizeaphysical asso-
ciation with rhesus tetherin and to overcome restriction by rhesus
tetherin, when expressed as a heterologous CD4 fusion protein.
EnvITM Downmodulates and Colocalizes with Rhesus
Tetherin in Infected Cells
We next asked whether SIV EnvITM could downmodulate teth-
erin from the surface of infected cells. Peripheral blood lympho-
cytes were infected with wild-type SIV, SIV Dnef, SIV DnefP,
and SIV DnefP with the Y721A mutation (SIV DnefP Y721A). Five
days after infection, the cultures were treated with IFNa and
stained 24 hr later for the surface expression of CD4 and tetherin
and for the intracellular expression of p27 capsid. Themean fluo-
rescence intensity (MFI) of tetherin expression on the cell surface
was compared for virus-infected (p27+) CD4+ lymphocytes.
Consistentwith a previous study showingNef-mediated downre-
gulation of rhesus tetherin in transfected cells (Jia et al., 2009),
a 2.0-fold decrease in the surface expression of tetherin was
observed for wild-type SIV versus SIV Dnef-infected cells (Fig-
ure 7A). A decrease in the surface expression of tetherin was
also observed in SIV DnefP-infected cells (Figure 7A). Although
the extent of tetherin downregulation was less than in wild-type
SIV-infected cells, this effect was completely eliminated by the
Y721A mutation in SIV DnefP Y721A-infected cells (Figure 7A).
Thus, similar to HIV-2 Env (Le Tortorec andNeil, 2009), the down-
modulation of rhesus tetherin by SIV EnvITM depends on the
tyrosine-based endocytosis motif in gp41.CellTo further investigate the fate of rhesus tetherin in SIV DnefP-
infected cells, we examined the subcellular distribution of Env
and tetherin in infected primary lymphocytes. In wild-type SIV-in-
fected cells, there was little overlap in the distribution of Env and
tetherin, and the intensity of tetherin staining was consistently
lower than in SIV Dnef-infected cells (Figure 7B and Figure S4),
perhaps reflecting a role for Nef in reducing the steady-state
levels of tetherin. In SIV Dnef-infected cells, Env and tetherin
exhibited similar distributions and greater colocalization, either
as a coincidence of their localization to the same subcellular
compartments or possibly as a result of a basal interaction
between wild-type Env and rhesus tetherin. However, in the
SIV DnefP-infected cells, the distribution of Env and tetherin
was more focal, and patches of intense colocalization were
observed at the plasma membrane and within intracellular
compartments (Figure 7B and Figure S4). These observations
were corroborated by comparing the Pearson’s correlation coef-
ficients for the colocalization of Env and tetherin in images of 20
randomly selected cells infected with each virus. The extent of
Env and tetherin colocalization was significantly higher for SIV
Dnef- versus wild-type SIV-infected cells (p < 0.001) and for
SIVDnefP- versus SIV Dnef-infected cells (p = 0.003) (Figure 7C).
The greater colocalization of Env and tetherin in SIV DnefP-
compared to SIV Dnef-infected cells suggests that, similar to
HIV-2 antagonism of human tetherin (Le Tortorec and Neil,
2009), EnvITM associates with rhesus tetherin in infected cells,
sequestering it from sites of virus budding at the plasma
membrane.
DISCUSSION
Most natural SIV isolates, including viruses of the SIVsmm/mac,
SIVagm and SIVcpz lineages, use Nef to counteract restriction
by tetherin in their non-human primate hosts (Jia et al., 2009;
Sauter et al., 2009; Zhang et al., 2009). Due to the absence of
sequences in the cytoplasmic domain of human tetherin neces-
sary for antagonism by Nef (Jia et al., 2009; Zhang et al., 2009),
this function was assumed by the Vpu protein of HIV-1 (Neil et al.,
2008; Van Damme et al., 2008), and the Env protein of HIV-2
(Le Tortorec and Neil, 2009). Thus, at least three different lentivi-
ral gene products have evolved to counteract tetherin. Yet the
significance of these countermeasures to lentiviral pathogenesis
is not well understood. Here, we show that compensatory
changes in the cytoplasmic tail of gp41 restore resistance to
tetherin in a nef-deleted strain of SIV that regained a pathogenic
phenotype in rhesus macaques. These results are consistent
with the adaptation of HIV-2 Env for antagonism of human teth-
erin and suggest that the ability to overcome restriction by teth-
erin is important for lentiviral pathogenesis.
HIV-2 Env internalizes and sequesters tetherin within the trans-
Golgi network, effectively removing it from sites of virus
assembly at the plasma membrane, by a mechanism that
depends on a conserved tyrosine-based endocytosis motif in
the cytoplasmic domain of gp41 and a physical interaction with
tetherin (Le Tortorec and Neil, 2009). Antagonism of rhesus teth-
erin by the Env protein of SIV DnefP (EnvITM) also requires the
endocytosis motif in gp41, and the selective coimmunoprecipi-
tation of EnvITM with rhesus tetherin suggests that a physical
interaction, either direct or via a bridging factor, occurs betweenHost & Microbe 9, 46–57, January 20, 2011 ª2011 Elsevier Inc. 53
Figure 7. Tetherin Is Downmodulated from the Cell Surface and Colocalizes with EnvITM in SIV DnefP-Infected Lymphocytes
(A) Activated primary rhesusmacaque lymphocytes were infectedwith wild-type SIV, SIVDnef, SIVDnefP, and SIVDnefPY721A. Five days after infection, the cells
were treated with IFNa, and stained 24 hr later for the surface expression of CD4 and tetherin (BST-2) and for the intracellular expression of SIV p27. The MFI of
BST-2 staining for lymphocytes infected with each virus is shown after gating on p27+ CD4+ cells.
(B) Virus-infected lymphocytes were examined by confocal microscopy for the colocalization of Env and BST-2. Twenty-four hours after the addition of IFNa, the
cells were fixed, permeabilized, and stained with monoclonal antibodies to BST-2 (green), Env (red), and with a nuclear dye (blue). The scale bar represents 1 mm.
(C) The extent of Env and tetherin colocalization was estimated by calculation of the Pearson’s correlation coefficients for images of 20 randomly selected cells
infectedwith each virus (see also Figure S4), and the differences in these valueswere compared for wild-type SIV- versus SIVDnef-infected cells and for SIVDnef-
versus SIV DnefP-infected cells with an unpaired Student’s t test.
See also Figure S4.
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from the cell surface and colocalized with Env to a greater extent
in SIV DnefP-infected lymphocytes than in SIV Dnef-infected
lymphocytes. These results suggest that, similar to HIV-2 Env,
EnvITM promotes the internalization and sequestration of rhesus
tetherin away from sites of virus release.
However, unlike HIV-2 Env antagonism of human tetherin,
which involves determinants in the extracellular domain of Env
(Abada et al., 2005; Le Tortorec and Neil, 2009), the cytoplasmic
domain of EnvITM is sufficient to antagonize rhesus tetherin.
Expression of the EnvITM tail as a CD4-Env fusion protein re-
sulted in a physical interaction with rhesus tetherin and rescued
virus release for SIV DenvDnef. Furthermore, whereas the A100D
mutation in the ectodomain of human tetherin abrogates antag-
onism by SIVagmTan and HIV-2 Env (Gupta et al., 2009; Lopez
et al., 2010), the corresponding mutation in rhesus tetherin
(A103D) had no effect on the anti-tetherin activity of EnvITM.
The specificity of EnvITM for rhesus tetherin is instead depen-
dent on sequences in the cytoplasmic domain of rhesus tetherin
(P3IL+R9KM) that differ from the sequences required for antago-54 Cell Host & Microbe 9, 46–57, January 20, 2011 ª2011 Elsevier Innism by Nef (G/D14DIWK18) (Jia et al., 2009; Zhang et al., 2009).
This is supported by the concordance of EnvITM binding and SIV
DnefP resistance to recombinant forms of tetherin in which resi-
dues 3–5 and 9–11 of rhesus and human tetherin were
exchanged. Thus, in contrast to the mechanism by which HIV-
2 and SIVagmTan Env antagonize human tetherin, EnvITM antag-
onism of rhesus tetherin is driven by specific determinants in the
cytoplasmic domains of each of these molecules.
While the Env protein of SIV DnefP has clearly acquired the
ability to antagonize rhesus tetherin, the effects of EnvITM versus
Env on virus release were not commensurate with differences in
tetherin binding and downregulation. The reasons for these
disparities are unclear but may be related to the difficulty of
comparing static measurements of protein-protein interactions
and cell-surface expression to the cumulative effects of an inher-
ently dynamic process. If EnvITM-tetherin complexes form tran-
siently during the process of antagonism, only a small fraction of
the EnvITM protein in a cell may bind to rhesus tetherin at a given
time. Furthermore, the biochemical conditions and multiple
wash steps required to observe the association of these proteinsc.
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extent of EnvITM-tetherin interactions in living cells. Dispropor-
tionate effects on virus release relative to tetherin downmodula-
tion were also observed for HIV-2 Env (Le Tortorec and Neil,
2009). As has been suggested for HIV-2 Env, EnvITM may
neutralize the antiviral effects of tetherin without significant
downmodulation, perhaps by redistributing the protein in the
plasma membrane away from sites of virus budding prior to
internalization. Paradoxically, this would reduce virus infectivity
by decreasing the amount of Env available for the assembly of
infectious virions and might account for additional compensa-
tory changes in SIV DnefP. The possibility that EnvITM may
redistribute tetherin is consistent with the detection of significant
amounts of EnvITM and tetherin on the surface of SIV DnefP-in-
fected cells and with previous studies showing that Vpu mutants
that cannot internalize tetherin are able to partially counteract
virus restriction (Miyagi et al., 2009; Schubert et al., 1996).
Relative to SIV Dnef, SIV DnefP exhibits increased replicative
capacity and pathogenicity in rhesus macaques. Five of six
animals infected with SIV DnefP developed moderate viral loads
that were detectable in plasma throughout the chronic phase of
infection (Alexander et al., 2003). Set-point viral loads 24 weeks
after infection were approximately two logs higher in SIV DnefP-
infected animals than in SIV Dnef-infected animals (Alexander
et al., 2003). The selective pressure to acquire specific substitu-
tions in gp41 that confer resistance to tetherin suggests that this
activity is important for optimal virus replication in vivo. However,
it should be noted that the ITM changes were not sufficient for
pathogenesis when introduced into SIV Dnef by themselves
(Alexander et al., 2003). The U3 deletion may contribute to the
replication of SIV DnefP by virtue of reducing the size of the viral
genome. Likewise, the ITM changes in gp41 result in a modest,
but reproducible, 2- to 3-fold increase in the fusogenicity of Env,
which may facilitate virus replication independently from their
role in opposing tetherin (Alexander et al., 2003). cNef may
also enhance virus replication through subtle effects on the
cell-surface expression of CD4 or by another mechanism that
remains to be defined. Thus, perhaps not surprisingly, other
compensatory changes, in addition to those that confer resis-
tance to tetherin, are likely to play a role in the increased replica-
tive capacity and pathogenicity of SIV DnefP.
The finding that the envelope glycoprotein of SIV can acquire
the ability to antagonize tetherin in the absence of Nef is entirely
consistent with the adaptation of HIV-2 Env for antagonism of
human tetherin. These observations also support the hypothesis
that adaptation to human tetherin may have contributed to the
epidemic spread of HIV-1 and HIV-2 (Evans et al., 2010; Sauter
et al., 2009). However, the use of Env to counteract tetherin may
come at a cost to the efficiency of virus replication. In contrast
to Nef or Vpu, which are small accessory proteins, Env is a large
protein (879aminoacids in thecaseof SIVmac239) that is essential
for virus replication. Consequently, the need to devote a substan-
tial fraction of the Env proteins produced by an infected cell to the
antagonism of tetherin, rather than to the assembly of infectious
virions, is likely to have a greater impact on viral fitness than the
use of Nef or Vpu to overcome this restriction. Indeed, this may
in part explain the lower level of virus replication, and the slower
rate of disease progression, for individuals infected with HIV-2
versus HIV-1 (de Silva et al., 2008).CellIn summary, we have identified compensatory genetic
changes that restore resistance to tetherin in a nef-deleted strain
of SIV that reverted to a pathogenic phenotype after serial
passage in rhesus macaques. Five amino acid substitutions in
the cytoplasmic tail of gp41 were sufficient to provide resistance
to rhesus tetherin, but not to human tetherin. These changes re-
sulted in a selective physical interaction with rhesus tetherin and
antagonism of rhesus tetherin by a mechanism similar to HIV-2
Env antagonism of human tetherin. Of the multitude of functional
activities that have been attributed to Nef, the acquisition of anti-
tetherin activity by Env in a nef-deleted strain of SIV that regained
a pathogenic phenotype indicates that this function is particu-
larly important for virus replication in vivo. Hence, these observa-
tions provide themost direct evidence to date that antagonismof
tetherin is important for lentiviral pathogenesis.
EXPERIMENTAL PROCEDURES
Plasmid DNA Constructs
Constructs for the expression of Env and Nef were based on pCGCG, and
constructs for the expression of tetherin were based on pcDNA3 as previously
described (Jia et al., 2009). Full-length proviral clones were assembled from
p239SpSp50, pSP72-239-30, pSP72-239-30Dnef, and p30 ITMDnefDUS138
(Alexander et al., 2003; Jia et al., 2009; Kestler et al., 1991; Regier and Desros-
iers, 1990). See the Supplemental Experimental Procedures for additional
details.
Virus Replication Assays in Primary Lymphocytes
Rhesus macaque PBMCs were CD8-depleted with anti-CD8 immunomag-
netic beads (Invitrogen), activated with concanavalin A (5 mg/ml) (Sigma-Al-
drich), and expanded in medium supplemented with IL-2 (20 U/ml) (NIH
AIDS Research and Reference Reagent Program). Activated lymphocytes
(2 3 106 cells) were infected with wild-type SIV, SIV Dnef, and SIV DnefP
(50 ng p27). Two days after infection, the cultures were divided andmaintained
in medium with or without IFNa (100 U/ml) (Sigma). Virus replication wasmoni-
tored by measurement of the accumulation of SIV p27 in the cell culture super-
natant by antigen-capture ELISA (Advanced Biosciences Laboratories).
Virus Release Assays
Virus release was measured by the accumulation of SIV p27 in the cell culture
supernatant and expressed as the percentage of maximal release in the
absence of tetherin according to previously described methods (Jia et al.,
2009). See the Supplemental Experimental Procedures for details.
Western Blots
Proteins were separated by electrophoresis on SDS-polyacrylamide gels,
transferred to polyvinylidene fluoride (PVDF) membranes, and detected on
western blots by probing with antibodies to Env, p55/p27, BST-2, Nef, HA,
CD4, and b-actin as previously described (Jia et al., 2009). Details are provided
in the Supplemental Experimental Procedures.
Coimmunoprecipitation Assays
293T cells (63 105 cells) were cotransfected with constructs expressing wild-
type and mutant forms of human or rhesus tetherin (2 mg) and either wild-type
Env, EnvITM, EnvITM Y721A, or CD4-Env fusion proteins (2 mg). Twenty-four
hours later, cells were lysed with RIPA buffer (200 ml) and incubated on ice
for 10 min. Insoluble cell debris was removed by centrifugation at 3000 rpm.
Precleared lysates were incubated on a rotating platform for 1 hr at 4C with
1 mg of the anti-tetherin monoclonal antibody HM1.24, generously provided
by Chugai Pharmaceutical (Kanagawa, Japan). Protein A sepharose beads
(50 ml) (GE Healthcare) were then added, and the incubation was continued
overnight at 4C. The beads were washed ten times in RIPA buffer (500 ml)
and boiled in 23 SDS sample buffer. Proteins were separated by SDS-
PAGE and detected by probing of western blots with the monoclonal anti-
bodies KK42 (NIH AIDS Research and Reference Reagent Program) andHost & Microbe 9, 46–57, January 20, 2011 ª2011 Elsevier Inc. 55
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Changes in SIV gp41 Afford Resistance to TetherinHM1.24 to detect SIV Env and BST-2 respectively, and a polyclonal antibody
to CD4 (Sigma-Aldrich) to detect the CD4-Env fusion proteins. See the Supple-
mental Experimental Procedures for additional details on western blots. Band
intensities were determined with ImageJ software (Abramoff et al., 2004).
Confocal Microscopy
Rhesus macaque PBMCs were activated with concanavalin A (5 mg/ml) and
expanded in medium supplemented with IL-2 (20 U/ml). Activated lympho-
cytes (23 106 cells) were infected with wild-type SIV, SIV Dnef, and SIV DnefP
(50 ng p27). Three days after infection, the cells were treated with IFNa
(1000 U/ml). Twenty-four hours later, the cells were washed and fixed for
5 min in 2% paraformaldehyde PBS. After three washes with PBS, the cells
were resuspended in 100 mM glycine diluted in 10% normal goat serum in
PBS with 0.2% fish skin gelatin, 0.1% Triton X-100, and 0.02% sodium azide
(10% NGS-PBS-FSG-Tx100-NaN3) for 15 min. The cells were then washed
three times in 10% NGS-PBS-FSG-Tx100-NaN3 and stained. The monoclonal
antibodies KK42 (IgG1) and HM1.24 (IgG2a) were used at a 1:250 and 1:500
dilutions to stain for Env and BST-2, respectively. The cells were subsequently
stained with Alexa-488- and Alexa-568-conjugated goat anti-mouse
secondary antibodies specific for IgG2a and IgG1 (Invitrogen) (1:1000), and
with TO-PRO3 (Invitrogen) (1:5000) to visualize cell nuclei. After staining, the
cells were washed and mounted on slides with antiquenching mounting-
medium (Vector Laboratories). Images were acquired with a Leica TCS SP5
II confocal microscope. ImageJ software was used to calculate the Pearson’s
correlation coefficients for the colocalization of Env and tetherin in images of
20 randomly selected cells (Zinchuk and Zinchuk, 2008). Differences in the
correlation coefficients for cells infected with each virus were compared with
an unpaired Student’s t test.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at doi:10.1016/j.
chom.2010.12.005.
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